Browsing Topic

ASX NTI

2 posts
FDA HQ

Neurotech bounces back from FDA rejection with new NTI164 baseline study

Neurotech (ASX:NTI) has bounced back from a recent fast-track status rejection from the FDA, now launching…
The FDA headquarters

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Neurotech International (NTI) has flagged to its shareholders that the FDA hasn't granted its product NTI164…